An interventional study of CBmed drug screening platform in Glioblastoma (GBM), sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Glioblastoma with a site in Austria — 7 open to participants now, 11 under way, 4 of them phase 3. Glioblastoma · Austria.
Among the 37 studies in Glioblastoma with a site in Austria, this one is the 30th largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 36th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →7 of the 37 studies in Glioblastoma with a site in Austria are open now. Recruiting first, the newest first:
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Austria, Australia, Belgium and 1 more country
Ages 18+
Vastra Gotaland Region · Sites in Austria, Denmark, Norway and 1 more country
Ages 18–70
Medical University of Vienna · Sites in Austria
Ages 18–75
European Organisation for Research and Treatment of Cancer - EORTC · Sites in Austria, Belgium, Czechia and 8 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Austria, France, Germany and 6 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 14
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 120 across the 35 interventional studies, 330 across the 2 observational. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 3 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glioblastoma with a site in Austria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT05450744Telix Pharmaceuticals (Innovations) Pty Limited131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Glioblastoma with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients will receive in addition to standard histology analysis also the PDC- based drug screening.
Patients will receive in addition to standard histology analysis also the PDC- based drug screening. The PDC-based drug screening will be performed only in accordance with the approved Performance Study Plan on subjects who have signed an informed consent form. Execution of the PDC-based drug screening is limited to the approved study investigators. Based on the results of the PDC-based drug screening, a molecular tumor board will formulate a personalized treatment approach. The personalized treatment recommendation will be communicated to the patient. Application of adjuvant
/ maintenance therapy will be evaluated to evaluate the proportion of patients scheduled for a reduced course of radio(-chemo)therapy fit enough to receive at least one day of systemic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive in addition to standard histology analysis also the PDC-based drug screening.
Diagnostic Test: CBmed drug screening platform
The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics
Percentage of patients
Percentage of patients receiving at least one day of maintenance systemic therapy in the timeframe of 4-6 weeks after completion of a short course radio(-chemo)therapy (40 Gy in 15 fractions)
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
PDC-based drug screening
Assess feasibility of a PDC-based drug screening approach in a multi-center study hroughout Austria and within the timeframe short course radio(-chemo)therapy (40 Gy in 15 fractions)
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
Quality of life assessment
Quality of life assessment based on verified questionnaires
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
Neurocognitive function
Assess the neurocognitive function using the NANO scale (neurological assessment in neuro- oncology)
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
Overall survival
Assess the overall survival
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
Progression free survival
Assess the progression free survival
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
Geriatric screening tools
Geriatric vulnerability will be assessed using the Geriatric-8 (G8) and Vulnerable Elders Survey 13 (VES-13) screening tools.
Time frame: From date of enrollment until the last follow up or the date of death from any causes, whichever came first, assessed up to 3 years
Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.
Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 19 months is below that.
Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →